AUTHORS
Ashwin Kishtagari, MBBS, MSCI, Stephen Oh, MD, PhD2, Michael Marrone, PhD, MPH3, Bryce Allen-Van Doren, PhD4, Camryn Craig5, Purvi Suthar6, Abiola Oladapo, PhD7, Michael Vredenburg, PhD8, Andrew T Kuykendall, MD9
AFFILIATIONS
1 Vanderbilt University Medical Center, Nashville, Tennessee, United States
2 Washington University School of Medicine, St. Louis, Missouri, United States
3 Sobi Inc., Waltham, Massachusetts, United States
4 Cardinal Health, Dublin, Ohio, United States
5 Cardinal Health, Dublin, Ohio, United States
6 Sobi Inc., Waltham, Massachusetts, United States
7 Sobi Inc., Waltham, Massachusetts, United States
8 Sobi Inc., Waltham, Massachusetts, United States
9 Moffit Cancer Center, Tampa, Florida, United States
ABSTRACT
Anemia is a major clinical burden in myelofibrosis (MF) associated with poor prognosis. Pacritinib (PAC), a JAK1-sparing inhibitor of JAK2/IRAK1/ACVR1, can be delivered at full dose regardless of cytopenias and has demonstrated hematological benefit in clinical trials (e.g., PERSIST-2, NCT02055781). Real-world evidence on Hb response and response durability with PAC remains limited. We evaluated these outcomes in a real-world cohort of patients with MF treated with PAC.
Data from EMOL Health, a community oncology electronic medical record data-aggregation platform, were used to identify pts with MF treated with PAC for ≥1 month between June 2022 and September 2025 with ≥6 months of follow-up from PAC initiation (index), unless death occurred earlier. Pts were evaluable for anemia response if they had Hb<10 g/dL at index, pre-index RBC transfusion data, and Hb and transfusion data while on PAC. At index, pts were classified per 2024 IWG-ELN criteria as transfusion-dependent anemia (TDA; ≥3 RBC units in the prior 12 weeks and most recent transfusion ≤28 days before index) or non-TDA (did not meet TDA criteria). Severe bicytopenia was defined as Hb<8 g/dL and platelet (PLT) count <50×10⁹/L at index. IWG-ELN 2024 Hb response was assessed hierarchically as best overall response, with major and minor responses mutually exclusive. For TDA, major response required a ≥1.5g/dL rolling 12-week average Hb increase and transfusion independence; minor response required a ≥50% reduction in transfusion burden. For non-TDA, major and minor responses required ≥1.5 and ≥1.0g/dL rolling 12-week average Hb increases, respectively, without transfusions. Duration of PAC treatment, anemia response, and OS were estimated using Kaplan-Meier (KM) methods.
Among 48 PAC-treated pts with Hb<10 g/dL at index, the median age was 77.0 years (Q1-Q3: 69.6-81.1), and 52.1% (25/48) were male. Most pts received PAC as their second JAK inhibitor (31/48, 64.6%), with a median interval of 23.3 months from MF diagnosis to PAC initiation. Among pts receiving PAC after a prior JAK inhibitor, ruxolitinib was the most common prior therapy (23/31, 74.2%), followed by fedratinib (7/31, 22.6%) and momelotinib (1/31, 3.2%). Most pts initiated PAC at a total daily dose of 400mg (35/48, 72.9%). At index, median Hb was 8.5g/dL (Q1-Q3: 7.7-9.3) and median PLT count was 50×10⁹/L (Q1-Q3: 28-122); 32 pts (66.7%) had severe bicytopenia at treatment initiation. The median follow-up duration from PAC initiation was 8.4 months (Q1-Q3: 6.0-18.2); the KM-estimated median duration of PAC treatment was 7.7 months (95% CI: 4.1-10.5).
Of the 46 pts evaluable for Hb response, 10 (21.7%) were TDA and 36 (78.3%) were non-TDA at index. During treatment, 19 pts (41.3%) achieved an IWG-ELN 2024 Hb response, including 15 (32.6%) major and 4 (8.7%) minor responses. Among pts with TDA at index, 3/10 (30.0%) achieved a major response and 3/10 (30.0%) achieved a minor response. Among pts with non-TDA at index, 12/36 (33.3%) achieved a major response and 1/36 (2.8%) achieved a minor response. Among IWG-ELN 2024 responders, the median Hb increase during the response-defining period was 2.1g/dL (Q1-Q3: 1.3-2.8) in pts with TDA at index (n=6) and 1.6g/dL (Q1-Q3: 1.6-1.7) in those with non-TDA at index (n=13). Overall, 78.9% (15/19) of responders achieved an Hb level ≥10.0 g/dL during treatment. PLT counts remained stable throughout follow-up, with median PLT counts of 63 (Q1-Q3: 35-146), 67 (Q1-Q3: 31-135), 72 (Q1-Q3: 29-125), and 73×10⁹/L (Q1-Q3: 41-134) at Days 30, 60, 90, and 180, respectively. The KM-estimated median duration of major or minor anemia response was 42.7 weeks overall (95% CI: 18.0-58.7; TDA responders: 27.6 weeks (95% CI: 11.9-NE) non-TDA responders: 58.7 weeks (95% CI: 14.0-NE)). The median KM-estimated OS was 21.8 months (95% CI: 12.2-NE), and the KM-estimated 6-month survival probability was 75.0% (95% CI: 60.2-85.0).
In this real-world cohort, PAC was associated with Hb improvement in a substantial proportion of pts with MF-associated anemia and severe cytopenias, in both TDA and non-TDA subgroups. The clinically meaningful and durable Hb responses in both TDA and non-TDA pts points to PAC’s potential for treatment of MF-associated anemia. These findings extend prior real-world observations of PAC by demonstrating durable anemia responses using IWG-ELN 2024 response criteria in an independent, curated data source.
DISCLOSURES
Ashwin Kishtagari, MBBS, MSCI: Geron Corporation - Current equity holder in publicly-traded company; Syndax - Current equity holder in publicly-traded company; Syndax - Current equity holder in private company; Servier Pharmaceuticals - Consultancy (Includes expert testimony)